We complete the intake.
Then we grade it.
Independent reviews of telehealth and compounded-pharmacy programs across seven categories of care. Each review uses a 4-dimensional grade (cost, intake honesty, sourcing transparency, screening rigor) and is updated whenever pricing or regulation shifts.
Two flagship reviews.
The compounded-GLP-1 deep dives.
LegUpRx Sublingual Semaglutide
$174/mo. The cheapest verified legal cash-pay GLP-1 we tracked in 2026 — 7.7× cheaper than Wegovy list. 503A patient-specific compounding, all 50 states.
Read the full review →LegUpRx Injectable Tirzepatide
$499/mo. Dual GIP/GLP-1 mechanism at roughly half the brand-name cash price. Includes a full regulatory-risk section on the post-shortage compounding landscape.
Read the full review →Coverage map.
How we grade.
Four dimensions, equal weight. Cost (total 12-month all-in), intake honesty (we complete it), sourcing transparency (503A vs 503B, pharmacy identity, API source), and screening rigor (what gets asked, what disqualifies).
Read the methodology